We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Swiss shuffle

2 Dec 2021 By Aimee Donnellan, Jeffrey Goldfarb

The $99 bln Aussie jab maker is in talks to buy iron-deficiency specialist Vifor for around $7 bln. CEO Paul Perreault has a track record of strong growth and winning M&A. The prospect of subpar returns and a looming patent expiry suggest his golden touch is losing its lustre.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)